Plus Therapeutics, Inc. (PSTV)
Develops radioactive treatments for brain cancers and tumors.
$3.74+0.00%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-74.6%
The outlook
PSTV is trading near its 52-week low, well below both its 50- and 200-day moving averages, reflecting a bearish near-term trend. Analyst coverage shows an average price target roughly 8.6x the current price, though this wide gap suggests limited consensus and high uncertainty. The stock scores poorly on momentum metrics despite the optimistic long-term target.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range4% of the way from its 52-week low to high
Price targetAvg target +863% vs current price
Analyst price target
~12-month · 4 analysts$36.00average target+862.6% vs now
Now $3.74
Low $12.00High $57.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$25.7M
52-wk high
$23.50
52-wk low
$2.90
50-day avg
$4.82
200-day avg
$8.71
Trailing P/E
0.2